Hong Wei, Li Songsong, Cai Yueqin, Zhang Tingting, Yang Qingrou, He Beihui, Yu Jianshun, Chen Zhiyun
The Second Central Laboratory, The First Affliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Key Laboratory of Integrative Chinese and Western Medicine for the Diagnosis and Treatment of Circulatory Diseases of Zhejiang Province, Hangzhou, China.
Front Pharmacol. 2020 Nov 12;11:529553. doi: 10.3389/fphar.2020.529553. eCollection 2020.
MicroRNAs (miRNAs) have emerged as potential therapeutic targets for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH). Traditional Chineses Medicine (TCM) plays an important role in the prevention or treatment of NAFLD/NASH. However, miRNA targets of TCM against NASH still remain largely unknown. Here, we showed that Yiqi-Bushen-Tiaozhi (YBT) recipe effectively attenuated diet-induced NASH in C57BL/6 mice. To identify the miRNA targets of YBT and understand the potential underlying mechanisms, we performed network pharmacology using miRNA and mRNA deep sequencing data combined with Ingenuity Pathway Analysis (IPA). Mmu-let-7a-5p, mmu-let-7b-5p, mmu-let-7g-3p and mmu-miR-106b-3p were screened as the main targets of YBT. Our results suggested that YBT might alleviate NASH by regulating the expression of these miRNAs that potentially modulate inflammation/immunity and oxidative stress. This study provides useful information for guiding future studies on the mechanism of YBT against NASH by regulating miRNAs.
微小RNA(miRNA)已成为非酒精性脂肪性肝病/非酒精性脂肪性肝炎(NAFLD/NASH)的潜在治疗靶点。传统中药(TCM)在NAFLD/NASH的预防或治疗中发挥着重要作用。然而,中药针对NASH的miRNA靶点仍 largely未知。在此,我们表明益气补肾调脂(YBT)方剂可有效减轻C57BL/6小鼠饮食诱导的NASH。为了鉴定YBT的miRNA靶点并了解潜在的作用机制,我们结合miRNA和mRNA深度测序数据并运用 Ingenuity Pathway Analysis(IPA)进行了网络药理学研究。Mmu-let-7a-5p、mmu-let-7b-5p、mmu-let-7g-3p和mmu-miR-106b-3p被筛选为YBT的主要靶点。我们的结果表明,YBT可能通过调节这些可能调节炎症/免疫和氧化应激的miRNA的表达来减轻NASH。本研究为指导未来关于YBT通过调节miRNA治疗NASH机制的研究提供了有用信息。